Charles River Laboratories International, Inc. $CRL Stake Lowered by Boston Trust Walden Corp

Boston Trust Walden Corp trimmed its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 6.4% during the first quarter, Holdings Channel reports. The firm owned 285,425 shares of the medical research company’s stock after selling 19,452 shares during the period. Boston Trust Walden Corp’s holdings in Charles River Laboratories International were worth $49,236,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also made changes to their positions in the stock. Jones Financial Companies Lllp grew its stake in Charles River Laboratories International by 167.6% during the 1st quarter. Jones Financial Companies Lllp now owns 1,715 shares of the medical research company’s stock worth $253,000 after buying an additional 1,074 shares during the last quarter. Empowered Funds LLC acquired a new stake in shares of Charles River Laboratories International in the 1st quarter worth about $418,000. American Century Companies Inc. increased its holdings in shares of Charles River Laboratories International by 41.9% in the 2nd quarter. American Century Companies Inc. now owns 5,469 shares of the medical research company’s stock worth $830,000 after acquiring an additional 1,616 shares during the period. Brown Advisory Inc. lifted its position in Charles River Laboratories International by 5.1% in the 2nd quarter. Brown Advisory Inc. now owns 2,333 shares of the medical research company’s stock valued at $354,000 after purchasing an additional 114 shares during the last quarter. Finally, California Public Employees Retirement System lifted its position in Charles River Laboratories International by 3.9% in the 2nd quarter. California Public Employees Retirement System now owns 84,605 shares of the medical research company’s stock valued at $12,837,000 after purchasing an additional 3,198 shares during the last quarter. Institutional investors own 98.91% of the company’s stock.

Insiders Place Their Bets

In other Charles River Laboratories International news, Director James C. Foster sold 75,000 shares of the company’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $225.00, for a total value of $16,875,000.00. Following the completion of the sale, the director directly owned 31,596 shares in the company, valued at $7,109,100. This represents a 70.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.30% of the stock is owned by company insiders.

Charles River Laboratories International Stock Up 0.7%

Charles River Laboratories International stock opened at $230.59 on Friday. Charles River Laboratories International, Inc. has a 52 week low of $144.26 and a 52 week high of $236.62. The stock has a market cap of $11.11 billion, a price-to-earnings ratio of -61.33, a PEG ratio of 2.62 and a beta of 1.39. The company’s 50-day moving average price is $180.60 and its two-hundred day moving average price is $184.34. The company has a current ratio of 1.36, a quick ratio of 1.03 and a debt-to-equity ratio of 0.90.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Thursday, May 7th. The medical research company reported $2.06 earnings per share for the quarter, topping analysts’ consensus estimates of $1.96 by $0.10. The company had revenue of $995.83 million during the quarter, compared to analyst estimates of $977.46 million. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The business’s revenue for the quarter was up 1.2% compared to the same quarter last year. During the same period in the prior year, the business posted $2.34 EPS. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. On average, analysts expect that Charles River Laboratories International, Inc. will post 11.05 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have commented on the stock. CLSA upgraded shares of Charles River Laboratories International from a “hold” rating to an “outperform” rating and upped their target price for the stock from $167.00 to $219.00 in a research report on Friday, May 29th. Morgan Stanley raised Charles River Laboratories International from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $185.00 to $220.00 in a report on Wednesday, June 17th. JPMorgan Chase & Co. reduced their price objective on Charles River Laboratories International from $165.00 to $160.00 and set a “neutral” rating for the company in a research report on Monday, April 13th. Weiss Ratings raised Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday. Finally, Royal Bank Of Canada started coverage on Charles River Laboratories International in a research report on Tuesday, April 14th. They issued an “outperform” rating and a $215.00 target price on the stock. Twelve analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $215.88.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.